Quarterly System Demo - Q2 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 26 June 2025, 09:00 (CEST) to 26 June 2025, 10:45 (CEST)
PRAC recommendations on safety signals
List of signals discussed at PRAC since September 2012
PRAC recommendations on signals adopted at the 2-5 June 2025 PRAC meeting
Requesting scientific advice or protocol assistance from EMA
Human medicines European public assessment report (EPAR): Levetiracetam Actavis Group, levetiracetam, Date of authorisation: 04/12/2011, Revision: 19, Status: Authorised
Human medicines European public assessment report (EPAR): Vyjuvek, beremagene geperpavec, Date of authorisation: 23/04/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Xenpozyme, olipudase alfa, Date of authorisation: 24/06/2022, Revision: 7, Status: Authorised
Annual activity report 2024
Human medicines European public assessment report (EPAR): Xelevia, sitagliptin, Date of authorisation: 21/03/2007, Revision: 41, Status: Authorised